| Name | Title | Contact Details |
|---|---|---|
Andrew Schafer |
Chief Technology Officer | Profile |
Palladio Biosciences, Inc., a private, venture capital-backed biotech company, was founded in 2015 to develop transformative medicines for orphan diseases of the kidney.
We operate with a “No Analog” mindset—continually pushing boundaries, navigating new terrain and unleashing fresh thinking. We are committed to seeking better outcomes which compels us to ask questions that have not been asked before or remain unresolved. We are driven by a desire to create meaningful impact across business, health and society to ease the burden on people living with chronic diseases. Intarcia is a rapidly emerging biotech company dedicated to redesigning the treatment, prevention and experience of chronic disease. Our cross-disciplinary teams include forward-thinking scientists and entrepreneurs collaborating in a fast-paced environment redefining the future of medicine.
Our vision is to become the leading innovative global life-sciences company that unlocks the potential of T-cell biology and combines it with the power of T-cell engineering excellence to provide cures for patients. Through our model of seamless and rapid integration of research, translational medicine, manufacturing science, clinical development and customer-centric approaches, we will design and deliver enhanced state-of-the-art solutions for patients in a host of disease areas using Chimeric Antigen Receptors (CARs), Gene edited T-Cells, T regulatory cells (Treg), and engineered T Cell Receptors (TCRs)
Cardiff Oncology, Inc. is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need.
Stolle Milk Biologics Inc is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.